Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
José Daniel SubielaWojciech KrajewskiDaniel A González-PadillaJan LaszkiewiczJavier TabordaJúlia AumatellMiguel Sanchez EncinasGiuseppe BasileMarco MoschiniJorge Caño-VelascoEnrique Lopez PerezPedro Del Olmo DuránAndrea GallioliAndrzej TukiendorfDavid D'AndreaJeremy Yuen-Chun TeohAlejandra Serna CéspedesRenate PilcherLuca AfferiFrancesco Del GiudiceJuan Gomez RivasSimone AlbisinniFrancesco SoriaGuillaume PloussardLaura S MertensPaweł RajwaEkaterina LaukhtinaBenjamin PradereKarl TullyFélix Guerrero-RamosÓscar Rodríguez-FabaMario Alvarez-MaestroJose Luis Dominguez-EscrigTomasz SzydełkoVictoria Gomez Dos SantosMiguel Ángel Jiménez CidreFrancisco Javier Burgos Revillanull nullPublished in: European urology oncology (2024)
Our research shows that a sustained response to bacillus Calmette-Guérin in patients can lead to favorable outcomes, serving as a viable alternative to cystectomy for select cases.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- skeletal muscle
- robot assisted
- spinal cord injury
- peritoneal dialysis
- prognostic factors
- neoadjuvant chemotherapy
- muscle invasive bladder cancer
- bacillus subtilis
- clinical trial
- rectal cancer
- type diabetes
- squamous cell carcinoma
- patient reported outcomes
- cross sectional
- lymph node
- radiation therapy
- double blind
- weight loss
- insulin resistance
- locally advanced